WARFARİNLE İLİŞKİLİ LÖKOSİTOKLASTİK VASKÜLİT VE CİLT NEKROZLU OLGU

Yıl 2016, Cilt: 30 Sayı: 2, 133 - 136, 01.10.2016

Emel Bulcun Aydanur Ekici Mehmet Ekici Ayşe Anil Karabulut Ahu Cerit

Öz

Oral antikoagülanlar venöz ve arteryal embolileri önlemede ve tedavisinde yaygın olarak kullanılan ajanlardır. Doku nekrozu ve lökositoklastik vaskülit (LV) warfarine bağlı cilt reaksiyonlarındandır. Biz burada warfarin kullanırken ortaya çıkan LV olgusunu sunduk. Altmış bir yaşında erkek hasta, kronik obstruktif akciğer hastalığı (KOAH), kalp yetmezliği tanısı ile takip edilen ve 5 ay önce pulmoner emboli tanısı alan ve warfarin kullanan hasta son 2 haftadır artan nefes darlığı, öksürük, balgam çıkarma şikayetleri ile başvurdu. Fizik muayenesinde ayaklarında yer yer makülopapüler döküntüleri vardı. Hastanın takipte ayaklarında makülopapüler döküntüleri arttı ve ödemi gelişti, alt eksremitelerinde nekroze görünümler ve sırtında makülopapüler döküntüler ortaya çıktı. Warfarine bağlı cilt nekrozu ön planda düşünülen hastanın coumadini kesildi. Cleaxan tedavisine geçildi. Hastaya cilt biopsisi yapıldı. LV ile uyumlu olarak değerlendirildi. Kolşisin ve prednol 40 mg başlandı. Hastanın bilateral bacaklarındaki ve sırtındaki lezyonlarda belirgin gerileme izlendi. Sonuç olarak, warfarin kullanan hastalarda yeni gelişen cilt bulguları dikkatlice değerlendirilmeli ve warfarinin potansiyel yan etkileri göz önünde bulundurulmalıdır.

Anahtar Kelimeler

Warfarin, lökositoklastik vaskülit

WARFARIN-INDUCED LEUKOCYTOCLASTIC VASCULITIS AND SCIN NECROSIS

Öz

Oral anticoagulants are commonly used to prevent and treat venous and arterial embolism.Warfarin induced skin reactions include tissue necrosis and leukocytoclastic vasculitis (LV). Warfarin-induced LV case is presented here. 61 years old male patient. He has been followed-up for the diagnosis of chronic obstructive pulmonary disease (COPD), cardiac failure. He had been diagnosed as pulmonary embolism and started to use warfarin 5 months ago and admitted to hospital with the complaints of progressive dyspnea, cough, and phlegm in the last 2 weeks. According to the physical examination, he had sporadic maculopapular rash. Maculopapular rash increased in his feet during follow-up, and edema developed. After a while, necrosis signs in lower extremities and maculopapular rash in his back were occurred. Main diagnosis was considered as warfarin-induced skin necrosis, and coumadin was ceased. Low molecular weight heparine treatment was initiated. According to skin biopsy, it was compatible with LV. Colchicine, prednol 40 mg were initiated. Significant lesion improvement was observed on the bilateral legs and back of the patient. In conclusion, New skin signs should be evaluated carefully and potential side effects should be considered in the patients on warfarin.

Anahtar Kelimeler

Warfarin, leukocytoclastic vasculitis

Kaynakça

• 1. Gallerani M, Manfredini R, Moratelli S. Nonhaemorrhagic adverse reactions of oral anticoagulant therapy. Int J Cardiol 1995; 49:1- 7.
• 2. Sallah S, Thomas DP, Roberts HR. Warfarin and heparin-induced skin necrosis and the purple toe syndrome: infrequent complications of anticoagulant treatment. Thromb Haemost 1997; 78: 785-90.
• 3. Essex DW, Wynn SS, Jin DK. Late-onset warfarin-induced skin necrosis: case report and review of the literature. Am J Hematol 1998; 57: 233-7.
• 4. Despoina D. Kakagia, Nikolaos Papanas, Efthimios Karadimas, and Alexandros Polychronidis Warfarin-Induced Skin Necrosis Ann Dermatol 2014; 26: 96-8.
• 5. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85.
• 6. Kurt M, Shorbagi A, Aksu S, Haznedaroglu I, Altundag K, Erkin G. Warfarin-induced skin necrosis and leukocytoclastic vasculitis in a patient with acquired protein C and protein S deficiency. Blood Coagul Fibrinolysis 2007; 18: 805-6.
• 7. Chien-Yi Hsu, Wei-Sheng Chen, Shih-Hsien Sung. Warfarin-induced Leukocytoclastic Vasculitis: A Case Report and Review of Literature. Intern Med 2012; 51: 601-6.
• 8. Calabrese LH, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis Rheum 1990; 33:1108-13.
• 9. Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol 2003; 48: 311-40.
• 10. Bircher AJ, Scherer K. Delayed cutaneous manifestations of drug hypersensitivity. Med Clin North Am 2010; 94: 711-25.
• 11. Tanay A, Yust I, Brenner S, Koffler M, Abramov AL. Dermal vasculitis due to coumadin hypersensitivity. Dermatologica 1982; 16: 178- 85.
• 12. Yaghoubian B, Ngo B, Mak M, Ostrzega E, Tesoro J, Mitani GH. Warfarin-induced leukocytoclastic vasculitis. Cutis 2005; 75: 329-38.
• 13. Chen KR, Carlson JA. Clinical approach to cutaneous vasculitis. Am J Clin Dermatol 2008; 9: 71-92.
• 14. Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother 2002; 36: 130-47.